GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Roivant Sciences Ltd (STU:87S) » Definitions » Capex-to-Operating-Income

Roivant Sciences (STU:87S) Capex-to-Operating-Income : 0.00 (As of Mar. 2025)


View and export this data going back to 2023. Start your Free Trial

What is Roivant Sciences Capex-to-Operating-Income?

Capex-to-Operating-Income measures a company's investments in physical assets such as property, industrial buildings or equipment to its operating income.

Roivant Sciences's Capital Expenditure for the three months ended in Mar. 2025 was €-0.75 Mil. Its Operating Income for the three months ended in Mar. 2025 was €-263.59 Mil.

GuruFocus do not calculate Capex-to-Operating-Income if the Operating Income is negative.


Roivant Sciences Capex-to-Operating-Income Historical Data

The historical data trend for Roivant Sciences's Capex-to-Operating-Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Roivant Sciences Capex-to-Operating-Income Chart

Roivant Sciences Annual Data
Trend Mar21 Mar22 Mar23 Mar24 Mar25
Capex-to-Operating-Income
- - - - -

Roivant Sciences Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Capex-to-Operating-Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Roivant Sciences's Capex-to-Operating-Income

For the Biotechnology subindustry, Roivant Sciences's Capex-to-Operating-Income, along with its competitors' market caps and Capex-to-Operating-Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Roivant Sciences's Capex-to-Operating-Income Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Roivant Sciences's Capex-to-Operating-Income distribution charts can be found below:

* The bar in red indicates where Roivant Sciences's Capex-to-Operating-Income falls into.


;
;

Roivant Sciences Capex-to-Operating-Income Calculation

Roivant Sciences's Capex-to-Operating-Income for the fiscal year that ended in Mar. 2025 is calculated as

Capex-to-Operating-Income=- Capital Expenditure / Operating Income
=- (-4.254) / -1030.155
=N/A

Roivant Sciences's Capex-to-Operating-Income for the quarter that ended in Mar. 2025 is calculated as

Capex-to-Operating-Income=- Capital Expenditure / Operating Income
=- (-0.75) / -263.593
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Roivant Sciences  (STU:87S) Capex-to-Operating-Income Explanation

Capex-to-Operating-Income assesses how much emphasis a company is placing upon investing in capital-intensive projects. The ratio is generally a good gauge to quantify how much focus on growth a company has. Typically, smaller companies that are still growing and expanding will have a higher Capex to Operating Income Ratio, since such businesses are likely investing more in physical assets. Lower ratios could indicate that a company has reached maturity and it is no longer pursuing aggressive growth.


Roivant Sciences Capex-to-Operating-Income Related Terms

Thank you for viewing the detailed overview of Roivant Sciences's Capex-to-Operating-Income provided by GuruFocus.com. Please click on the following links to see related term pages.


Roivant Sciences Business Description

Traded in Other Exchanges
Address
50 Broadway, 7th Floor, London, GBR, SW1H 0BD
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.

Roivant Sciences Headlines

No Headlines